[1] Gandham SK, Rao M, Shah A, et al. Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer [J]. Mol Ther Oncolytics, 2022, 25: 57-68. DOI: 10.1016/j.omto.2022.03.005.
[2] 国家卫生健康委员会医政司,中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2023版)[J]. 协和医学杂志,2023,14(4):706-733. DOI:10.12290/xhyxzz.2023-0315.
[3] He C, Peng C, Shu X, et al. Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis [J]. Gastric Cancer, 2022, 25(5): 837-849. DOI: 10.1007/s10120-022-01302-z.
[4] Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer [J]. Lancet, 2024, 404(10449): 294-310. DOI: 10.1016/S0140-6736(24)00360-X.
[5] Cheong JK, Tang YC, Zhou L, et al. Advances in quantifying circulatory microRNA for early disease detection [J]. Curr Opin Biotechnol, 2022, 74: 256-262. DOI: 10.1016/j.copbio.2021.12.007.
[6] Ellakwa DE, Mushtaq N, Khan S, et al. Molecular functions of microRNAs in colorectal cancer: recent roles in proliferation, angiogenesis, apoptosis, and chemoresistance [J]. Naunyn Schmiedebergs Arch Pharmacol, 2024, 397(8): 5617-5630. DOI: 10.1007/s00210-024-03076-w.
[7] 汤守元,兰国玉,黄耿,等. 过表达miR-4731-5p通过调节PRR11表达对结直肠癌HT-29细胞增殖和凋亡的影响[J]. 国际医药卫生导报,2021,27(24):3777-3780. DOI:10.3760/cma.j.issn.1007-1245.2021.24.006.
[8] Lin Y, Zhao W, Lv Z, et al. The functions and mechanisms of long non-coding RNA in colorectal cancer [J]. Front Oncol, 2024, 14: 1419972. DOI: 10.3389/fonc.2024. 1419972.
[9] Kzar Al-Shukri HH, Abdul-Jabbar Ali S, Al-Akkam KA, et al. The role of exo-miRNA in diagnosis and treatment of cancers, focusing on effective miRNAs in colorectal cancer [J]. Cell Biol Int, 2024, 48(3): 280-289. DOI: 10.1002/cbin.12122.
[10] 耿松,卢清军,任翔,等. MicroRNAs在结直肠炎癌转化过程中的作用[J]. 国际医药卫生导报, 2023, 29(7): 903-909. DOI:10.3760/cma.j.issn.1007-1245.2023.07.004.
[11] Yang F, Xuan G, Chen Y, et al. MicroRNAs are key molecules involved in the gene regulation network of colorectal cancer [J]. Front Cell Dev Biol, 2022, 10: 828128. DOI: 10.3389/fcell.2022.828128.
[12] Chen Y, Liu F, Chen X, et al. microRNA-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation [J]. BMC Cancer, 2024, 24(1): 26. DOI: 10.1186/s12885-023-11766-6.
[13] Huang L, Ding W, Wu H, et al. miR-497/195 cluster affects the development of colorectal cancer by targeting FRA1 [J]. Mol Biotechnol, 2024, 66(5): 1019-1030. DOI: 10.1007/s12033-023-01000-w.
[14] Li F, Zhang M, Yin X, et al. Exosomes-derived miR-548am-5p promotes colorectal cancer progression [J]. Cell Mol Biol (Noisy-le-grand), 2023, 69(12): 104-110. DOI: 10.14715/cmb/2023.69.12.17.
[15] Chen Q, Li Y, Lu T, et al. miR-373 promotes invasion and metastasis of colorectal cancer cells via activating ERK/MAPK pathway [J]. Sci Rep, 2024, 14(1): 124. DOI: 10.1038/s41598-023-49565-5.
[16] Zhang J, Pan Y, Jin L, et al. Exosomal-miR-522-3p derived from cancer-associated fibroblasts accelerates tumor metastasis and angiogenesis via repression bone morphogenetic protein 5 in colorectal cancer [J]. J Gastroenterol Hepatol, 2024, 39(1): 107-120. DOI: 10.1111/jgh.16345.
[17] Shibamoto J, Arita T, Konishi H, et al. Roles of miR-4442 in colorectal cancer: predicting early recurrence and regulating epithelial-mesenchymal transition [J]. Genes (Basel), 2023, 14(7): 1414. DOI: 10.3390/genes14071414.
[18] Wautier JL, Wautier MP. Old and new blood markers in human colorectal cancer [J]. Int J Mol Sci, 2022, 23(21): 12968. DOI: 10.3390/ijms232112968.
[19] Dohmen J, Semaan A, Kobilay M, et al. Diagnostic potential of exosomal microRNAs in colorectal cancer [J]. Diagnostics (Basel), 2022, 12(6): 1413. DOI: 10.3390/diagnostics12061413.
[20] Xu J, Pan L, Wu D, et al. Comparison of the diagnostic value of various microRNAs in blood for colorectal cancer: a systematic review and network meta-analysis [J]. BMC Cancer, 2024, 24(1): 770. DOI: 10.1186/s12885-024-12528-8.
[21] Zhang C, Zhang L, Huang Q, et al. Diagnostic and screening potential of plasma exosome miR-99b-5p and its combination with other miRNAs for colorectal cancer [J]. Oncol Lett, 2024, 28(4): 461. DOI: 10.3892/ol.2024.14594.
[22] Amiri-Dashatan N, Koushki M, Ahmadi NA, et al. Diagnostic and prognostic value of miR-451 expression in colorectal cancer: a meta-analysis [J]. Asian Pac J Cancer Prev, 2024, 25(6): 1903-1910. DOI: 10.31557/APJCP.2024.25.6.1903.
[23] Mahmoudivar S, Zarredar H, Asadi M, et al. Serum miR-23 and miR-150 profiles as biomarkers for predicting recurrence following surgical intervention in colorectal cancer patients [J]. Rep Biochem Mol Biol, 2024, 12(4): 540-549. DOI: 10.61186/rbmb.12.4.540.
[24] Fabijanec M, Hulina-Tomašković A, Štefanović M, et al. MicroRNA-193a-3p as a valuable biomarker for discriminating between colorectal cancer and colorectal adenoma patients [J]. Int J Mol Sci, 2024, 25(15): 8156. DOI: 10.3390/ijms25158156.
[25] Bakhsh T, Alhazmi S, Alburae NA, et al. Exosomal miRNAs as a promising source of biomarkers in colorectal cancer progression [J]. Int J Mol Sci, 2022, 23(9): 4855. DOI: 10.3390/ijms23094855.
[26] Raonić J, Ždralević M, Vučković L, et al. miR-29a expression negatively correlates with Bcl-2 levels in colorectal cancer and is correlated with better prognosis [J]. Pathol Res Pract, 2024, 262: 155491. DOI: 10.1016/j.prp.2024.155491.
[27] Christodoulou S, Sotiropoulou CD, Vassiliu P, et al. MicroRNA-675-5p overexpression is an independent prognostic molecular biomarker of short-term relapse and poor overall survival in colorectal cancer [J]. Int J Mol Sci, 2023, 24(12): 9990. DOI: 10.3390/ijms24129990.
[28] Cui W, Bai X, Bai Z, et al. Exploring the expression and clinical significance of the miR-140-3p-HOXA9 axis in colorectal cancer [J]. J Cancer Res Clin Oncol, 2024, 150(2): 47. DOI: 10.1007/s00432-023-05592-3.
[29] Belova VA, Spirina LV, Avgustinovich AV, et al. New perspectives in colorectal cancers treatment, the role of microRNAs [J]. Curr Drug Targets, 2024, 25(11): 715-723. DOI: 10.2174/0113894501304351240703113651.
[30] Lu J, Jin Z, Jin X, et al. Prognostic value and potential regulatory relationship of miR-200c-5p in colorectal cancer [J]. J Biochem Mol Toxicol, 2024, 38(8): e23770. DOI: 10.1002/jbt.23770.
[31] Bai T, Zhang M, Liu Y, et al. WITHDRAWN: the clinical significance and expression level of miR-411-5p in colorectal cancer [J]. Altern Ther Health Med, 2024: AT10571.
[32] Tao L, Song P, Shao L, et al. miR-129-2-3p inhibits colon cancer cell proliferation by down-regulating the expression of BZW1 [J]. Arab J Gastroenterol, 2024, 25(1): 42-50. DOI: 10.1016/j.ajg.2023.11.005.
[33] Liu J, Yue K, Yang J, et al. miR-330-5p suppress cell growth and invasion via disrupting HSF4-mediated MACC1/STAT3 pathway in colorectal cancer [J]. Front Biosci (Landmark Ed), 2024, 29(2): 53. DOI: 10.31083/j.fbl2902053.
[34] Peng C, Li X, Yao Y, et al. MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3 [J]. Cancer Biol Ther, 2024, 25(1): 2373497. DOI: 10.1080/15384047.2024.2373497.
[35] Khalili E, Afgar A, Rajabpour A, et al. MiR-548c-3p through suppressing Tyms and Abcg2 increases the sensitivity of colorectal cancer cells to 5-fluorouracil [J]. Heliyon, 2023, 9(11): e21775. DOI: 10.1016/j.heliyon.2023.e21775.
|